Received Oct 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Extra dose administered; Late Dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 56-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received on08-NOV-2021). On 24-SEP-2025, the patient received the 3rd dose of Shingrix. On 13-DEC-2022, the patient received the 2nd dose of Shingrix. On 13-DEC-2022, not applicable after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Late Dose). On 24-SEP-2025, the patient experienced extra dose administered (Verbatim: Extra dose administered). The outcome of the extra dose administered and drug dose administration interval too long were not applicable. Additional Information: GSK Receipt Date: 24-SEP-2025 The reporter had a patient that got injected with a third dose of Shingrix and he/she was wondering if there was any information or recommendations. The reporter consented to follow up.